In this study, we have demonstrated the ability of the new anti-EMMPRIN monoclonal antibody hMR18-mAb to inhibit the activation of the EMT program and induce dormancy in three tumor cell lines of breast cancer and oral squamous cell carcinoma (OSCC). This evidence concerns the gene BSG and breast cancer.